Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
& i* R: l# P6 I6 s
+ V1 J# j) Q5 u* @% p6 F6 s9 ]$ O
Sub-category:$ U' v- |$ |' {4 N: u& K. x
Molecular Targets
8 }' U, X2 `$ b: d; k. x
8 w! S7 T4 H! N. y( z0 n8 \9 F# J0 y @2 L4 B. |/ e3 m) P
Category:& R w6 U0 D. y3 D* C, R4 T
Tumor Biology ( E4 m, u7 g; P6 h
5 e+ @" Y: [: o1 Q; H) `* }$ S
& j& _' H& o, B5 pMeeting:
l- T6 ~6 v! \! b2 q, ?& I) O! W, i2011 ASCO Annual Meeting 7 J* e) H! ^5 }# e, W
$ Z: K/ X+ k. p" w, y
* \4 i$ P7 m+ P/ L, w0 z& WSession Type and Session Title:( u% R* F" ^" X+ r m6 H9 d& ? d
Poster Discussion Session, Tumor Biology
5 p0 C& X8 @0 Y s$ k2 n `
0 P7 ^( d1 s0 g) l+ b& o. [' c) G: U) C+ ^1 t( D6 ?7 C
Abstract No:
3 z$ x" `3 @; A; |! ]6 t B10517 : N2 j$ P8 E/ a$ b* J0 n5 t8 J) \
# F7 H5 |4 p8 j3 \& S+ Z: x& P- O* ^4 C& h% |$ k* R. x
Citation:- u; _- P+ o q% `9 _/ H
J Clin Oncol 29: 2011 (suppl; abstr 10517)
6 S3 M# I3 X' F$ ^- y" b9 z0 G' k# [! |4 h! {# c1 v* c
" Y# T4 |8 q1 P2 I1 sAuthor(s):$ @4 Q. s" M+ t; @* z% j$ Z# w. z
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
! B2 ~9 S3 u' f: v+ `+ `4 J% f0 D) U" I
: |- E* q, G3 n( }5 m+ \" G% W' p* q/ i' Y% n7 A( b
) k; O$ d9 K+ y1 B+ \7 L! {5 Q
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ f* x. Q7 C$ V n+ d3 v1 p
. [9 V6 p1 v# N' p% ~! l8 R; s' SAbstract Disclosures
) u! N7 m! S* K' `; ]) b7 X, T
. I1 e) K/ }# U( w" yAbstract:
. d# v/ ^3 y/ n9 X1 I: q6 h6 {/ f/ ^+ }( q* f0 H7 K7 _! l
" n+ C: p- P/ i/ u0 J
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.) d f5 U! i) `, l; ]
2 b. R, G8 s' Q0 ]4 l" n4 m/ U
, n- ]2 H$ K' V9 o, W" u+ f! ^
|
卡度尼利单抗效果怎么样？
病友用卡度效果怎么样？大概多久耐药的……我们用了三次后准备换方案了，卡度尼利单抗
令肿瘤患者崩溃的化疗副作用，或可一
作者：seacat
恶心呕吐是化疗常见的不良反应，也是让患者很难受的不良反应。目前临床
肺部进展，脑膜稳定，单倍阿美20个月
我母亲23年4月确诊肺腺癌即脑膜转，鞘注了几次后单倍吃阿美20个月了，最近检查肺部略
HER2突变肺癌诊疗实现新突破，HER2检
作者：seacat
近几年来靶向和免疫疗法的发展显著改善了肺癌患者的生存期，但仍有一部
父亲晚期肺癌即将迈入第7年，这是我
讲述者：郭先生整理者：pear
2018年4月底，父亲因长期右肩胛骨疼痛、脸部及颈部肿大而
显身卡
